Skip to content
Home/Companies/Healthcare/Evommune
EV

Evommune

Healthcare·France·Exited 2025·Held 4yr

Evommune is a healthcare company, headquartered in France.

Entry
2021
Hold
4yr
Exit
2025
Est. EV
–

Who owns Evommune?

Evommune was owned by Andera Partners through BioDiscovery 5 (2017 vintage) from 2021 to 2025, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQFrance
SectorHealthcare
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2025

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Exited 2024
HealthcareFrance· 2021
to
Nyxoah
Active
HealthcareBelgium· 2020
AgoMab
Exited 2026
HealthcareFrance· 2019
to
AM Pharma
Active
HealthcareNetherlands· 2019
Arvelle
Exited 2021
HealthcareSwitzerland· 2019
to
Exciva
Active
HealthcareUS· 2019

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
4ways
Active
ECI PartnersUK
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abcam (exited)
Active
EMV CapitalUK
Data refreshed weekly · Sourced from public filings